Skip to main content
. 2022 Nov 11;17:286. doi: 10.1186/s13019-022-02032-0

Table 1.

Perioperative and postoperative results of the patients

Variables TPFF coverage (n = 53) Non-coverage (n = 134) p value
Age, years (mean ± SD) 62.83 60.60 0.064
Gender 0.108
 Male 44 (83.0) 126 (94.0)
 Female 9 (17.0) 8 (6.0)
Operative side [n (%)] 0.042
 Left 45 (84.9) 94 (70.1)
 Right 8 (15.1) 40 (29.9)
Co-morbidities [n (%)] 0.346
 Diabetes 11 (20.8) 15 (11.2)
 Cardiac disorder 2 (3.8) 10 (7.5)
 Hypertension 4 (7.5) 6 (4.5)
 Multiple 3 (5.7) 7 (5.2)
 None 33 (62.3) 96 (73.1)
FEV1 (lt) 2.14 ± 0.56 2.26 ± 0.56 0.187
FEV1 (%) 75.23 ± 14.25 84.43 ± 78.56 0.403
Preoperative serum albümine (mean ± SD) 4.28 ± 0.70 4.08 ± 0.45 0.023
Neoadjuvant therapy [n (%)] 0.176
 No 35 (68.6) 105 (78.9)
 Yes 16 (31.4) 28 (21.1)
Operation time (minutes) (mean ± SD) 224.53 ± 73.53 200.65 ± 95.91 0.101
Drainage time (days) (mean ± SD) 3.72 ± 2.24 3.92 ± 2.48 0.673
Hospitalization time (days) (mean ± SD) 5.92 ± 3.39 6.27 ± 3.23 0.592
Tumor size (mean ± SD) 5.21 ± 2.16 5.23 ± 2.31 0.951
Surgical margin to the main bronchus 2.51 ± 1.82 2.13 ± 1.42 0.180
Adjuvant chemotherapy [n (%)] 0.621
 No 22 (41.5) 50 (37.6)
 Yes 31 (58.5) 83 (62.4)
Adjuvant radiotherapy [n (%)] 0.424
 No 33 (78.6) 65 (84.4)
 Yes 9 (21.4) 12 (15.6)
Pathological stage [n (%)] 0.238
 Stage I 8 (15.1) 11 (12.6)
 Stage II 15 (28.3) 37 (42.5)
 Stage III 30 (56.6) 39 (44.8)
BPF [n (%)] 0.044
 No 52 (98.1) 119 (88.8)
 Yes 1 (1.9) 15 (11.2)